Cargando…

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility

Detalles Bibliográficos
Autores principales:	Kahlmeter, Gunnar, Cantón, Rafael, Giske, Christian G., Turnidge, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438218/ https://www.ncbi.nlm.nih.gov/pubmed/32827714 http://dx.doi.org/10.1016/j.cmi.2020.08.008

Ejemplares similares

Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing
por: Matuschek, Erika, et al.
Publicado: (2022)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory
por: Guinea, Jesús
Publicado: (2020)

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

Instruction videos from EUCAST
Publicado: (2020)

The EUCAST rapid disc diffusion method for antimicrobial susceptibility testing directly from positive blood culture bottles
por: Jonasson, Emma, et al.
Publicado: (2020)

EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories
por: Åkerlund, Anna, et al.
Publicado: (2020)

Assessing the quality of the anaerobic environment — a method developed to support EUCAST disk diffusion of anaerobic bacteria
por: Justesen, Ulrik Stenz, et al.
Publicado: (2023)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study
por: Haldorsen, Bjørg, et al.
Publicado: (2018)

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study
por: Haldorsen, Bjørg, et al.
Publicado: (2018)

Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?
por: Marchese, Anna, et al.
Publicado: (2012)

Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines
por: Dabas, Yubhisha, et al.
Publicado: (2017)

Usefulness of EUCAST rapid antibiotic susceptibility breakpoints and screening cut-off values directly from blood cultures for the inference of β-lactam resistance mechanisms in Enterobacterales
por: Cerrudo, V, et al.
Publicado: (2023)

New definitions of susceptibility categories EUCAST 2019: clinic application
por: Díaz, Sandra G. Nabal, et al.
Publicado: (2022)

The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing
por: Vahedi-Shahandashti, Roya, et al.
Publicado: (2023)

Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
por: Meletiadis, Joseph, et al.
Publicado: (2022)

Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms
por: Wolfensberger, Aline, et al.
Publicado: (2013)

Time to switch from CLSI to EUCAST? A Southeast Asian perspective
por: Cusack, T.P., et al.
Publicado: (2019)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

Aerococcus urinae and Aerococcus sanguinicola: Susceptibility Testing of 120 Isolates to Six Antimicrobial Agents Using Disk Diffusion (EUCAST), Etest, and Broth Microdilution Techniques
por: Carkaci, Derya, et al.
Publicado: (2017)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
por: Jørgensen, Karin Meinike, et al.
Publicado: (2019)

Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Test for Enterobacterales-Containing Blood Cultures in China
por: Shan, Yuzhang, et al.
Publicado: (2022)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes
por: Papadimitriou-Olivgeris, Matthaios, et al.
Publicado: (2020)

Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in Candida glabrata
por: Knoll, Miriam Alisa, et al.
Publicado: (2022)

In vitro antifungal susceptibilities of six antifungal drugs against clinical Candida glabrata isolates according to EUCAST
por: Fatahinia, Mahnaz, et al.
Publicado: (2020)

A New High-Throughput-Screening-Assay for Photoantimicrobials Based on EUCAST Revealed Unknown Photoantimicrobials in Cortinariaceae
por: Fiala, Johannes, et al.
Publicado: (2021)

Haemophilus influenzae blood-stream infection and third-generation cephalosporin susceptibility testing: a comparative case study using EUCAST and CLSI guidelines
por: Merlino, John, et al.
Publicado: (2023)

In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values
por: Jang, Min Joong, et al.
Publicado: (2013)

Prevalence of susceptibility patterns of opportunistic bacteria in line with CLSI or EUCAST among Haemophilus parainfluenzae isolated from respiratory microbiota
por: Kosikowska, Urszula, et al.
Publicado: (2020)

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications
por: Rogers, Thomas R, et al.
Publicado: (2022)

Multicentre Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) Extending Analysis to 16–20 Hours Reading Time
por: Bianco, Gabriele, et al.
Publicado: (2022)

Fully Automated EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) from Positive Blood Cultures: Diagnostic Accuracy and Implementation
por: Cherkaoui, Abdessalam, et al.
Publicado: (2022)

Adecuación de la prescripción de antibióticos antipseudomónicos tras los cambios en los criterios EUCAST 2019
por: Herranz-Bayo, Elena, et al.
Publicado: (2023)

Analytical Performance and Potential Clinical Utility of EUCAST Rapid Antimicrobial Susceptibility Testing in Blood Cultures after Four Hours of Incubation
por: Ekwall-Larson, Anna, et al.
Publicado: (2023)

Comparison of the Micronaut-AM System and the EUCAST Broth Microdilution Reference Method for MIC Determination of Four Antifungals against Aspergillus fumigatus
por: Gyurtane Szabo, Nikolett, et al.
Publicado: (2023)

342. Multicenter Evaluation of Fosfomycin MIC Results for Enterobacterales Using EUCAST V11 Breakpoints (i.v. and oral for uncomplicated UTI only, E. coli) on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mmj6eqg5ji2q9fdofh42bm551o